Correlation between monocyte count and progression of atherosclerosis in type2 diabetes

Correlation between monocyte count and progression of atherosclerosis in type2 diabetes - Diabetes-Monocyte study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003526

Enrollment

360

Registered

2010-04-23

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetic patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type2 Diabetic patients

Exclusion criteria

Exclusion criteria: 1.patients with infectious disease 2.patients with liver disfunction 3.patients with blood disease 4.Pregnant woman 5.other patients who are judged as unsuitable by investigators

Design outcomes

Primary

Measure	Time frame
1: correlation between monocyte count and IMT. 2: correlation between monocyte count and PWV.	—

Secondary

Measure	Time frame
1: correlation between leukocyte count and several factors as follow:TC, LDL, HDL-C, TG, HbA1c, HOMA-IR, TNFalpha, IL-6, adiponectin, solble insulin receptor. 2: correlation between leukocyte count and IMT. 3: correlation between leukocyte count and PWV. 4: correlation between leukocyte count and several factors as follow:TC, LDL, HDL-C, TG, HbA1c, HOMA-IR, TNFalpha, IL-6, adiponectin, solble insulin receptor.	—

Measure

Time frame

1: correlation between leukocyte count and several factors as follow:TC, LDL, HDL-C, TG, HbA1c, HOMA-IR, TNFalpha, IL-6, adiponectin, solble insulin receptor. 2: correlation between leukocyte count and IMT. 3: correlation between leukocyte count and PWV. 4: correlation between leukocyte count and several factors as follow:TC, LDL, HDL-C, TG, HbA1c, HOMA-IR, TNFalpha, IL-6, adiponectin, solble insulin receptor.

—

Countries

Japan

Contacts

Public ContactTakeshi Matsumura

Faculty of Life Sciences, Kumamoto University Department of Metabolic Medicine

takeshim@gpo.kumamoto-u.ac.jp096-373-5169

Outcome results